Compile Data Set for Download or QSAR
Report error Found 197 Enz. Inhib. hit(s) with all data for entry = 10327
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528251(US11180494, Example 121)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528250(US11180494, Example 120)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528253(US11180494, Example 123)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528254(US11180494, Example 124)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528257(US11180494, Example 127)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528256(US11180494, Example 126)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528049(US11180494, Example 1)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528261(US11180494, Example 131)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528263(US11180494, Example 133)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528235(US11180494, Example 105)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528234(US11180494, Example 104)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528237(US11180494, Example 107)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528236(US11180494, Example 106)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528239(US11180494, Example 109)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528220(US11180494, Example 93 | US11180494, Example 108)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528240(US11180494, Example 111 | US11180494, Example 110)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528243(US11180494, Example 113)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528245(US11180494, Example 115)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528244(US11180494, Example 114)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528247(US11180494, Example 117)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528246(US11180494, Example 116)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528248(US11180494, Example 118)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528149(US11180494, Example 25)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528284(US11180494, Example 152)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528147(US11180494, Example 24)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528283(US11180494, Example 151)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528151(US11180494, Example 27)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528150(US11180494, Example 26)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528285(US11180494, Example 153)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528153(US11180494, Example 29)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528326(US11180494, Example 155B)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528152(US11180494, Example 28)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528287(US11180494, Example 155A)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528155(US11180494, Example 31)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528289(US11180494, Example 158)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528154(US11180494, Example 30)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528288(US11180494, Example 157)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528157(US11180494, Example 33)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528156(US11180494, Example 32)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528290(US11180494, Example 159)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528293(US11180494, Example 162A)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528292(US11180494, Example 161)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528161(US11180494, Example 37)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528160(US11180494, Example 36)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528296(US11180494, Example 165)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528295(US11180494, Example 164)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528266(US11180494, Example 136)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528271(US11180494, Example 141)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528138(US11180494, Example 15)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM528137(US11180494, Example 14)
Affinity DataIC50: 50nMAssay Description:The biochemical potency of compounds was determined using a proximity-based assay (ALPHASCREEN , Perkin Elmer, Waltham, Mass.) as described previousl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

Displayed 1 to 50 (of 197 total ) | Next | Last >>
Jump to: